Aktienanalyse zu Bioatla Inc (BCAB)BCABBioatla Inc

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

BioAtla Inc is not a good buy right now due to its significant financial losses and poor stock performance. The current price is $1.74, which is a staggering 96.60% lower than its 1-year high of $71.50. Furthermore, the company has reported a negative net income of -$6,344,000 in Q1 2026, and a forward P/E ratio of 0 indicates uncertainty about future earnings. The recent hedge fund selling activity has increased by 760.39%, signaling a lack of confidence among institutional investors, which adds to the risk of holding this stock.